These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12088943)

  • 21. The potency (ED50) and cardiovascular effects of rapacuronium (Org 9487) during narcotic-nitrous oxide-propofol anesthesia in neonates, infants, and children.
    Kaplan RF; Fletcher JE; Hannallah RS; Bui DT; Slaven JS; Darrow EJ; Tsai KT
    Anesth Analg; 1999 Nov; 89(5):1172-6. PubMed ID: 10553829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapacuronium redux.
    Schulman SR
    Anesth Analg; 2002 Mar; 94(3):483-4. PubMed ID: 11867361
    [No Abstract]   [Full Text] [Related]  

  • 23. Reversal of rapacuronium block during propofol versus sevoflurane anesthesia.
    Zhou TJ; Tang J; White PF; Joshi GP; Wender R; Murphy MT; Chiu JW; Webb T
    Anesth Analg; 2000 Mar; 90(3):689-93. PubMed ID: 10702458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism.
    Jooste E; Klafter F; Hirshman CA; Emala CW
    Anesthesiology; 2003 Apr; 98(4):906-11. PubMed ID: 12657852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia.
    Levy JH; Pitts M; Thanopoulos A; Szlam F; Bastian R; Kim J
    Anesth Analg; 1999 Aug; 89(2):290-5. PubMed ID: 10439732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-response and onset/offset characteristics of rapacuronium.
    Kopman AF; Klewicka MM; Ghori K; Flores F; Neuman GG
    Anesthesiology; 2000 Oct; 93(4):1017-21. PubMed ID: 11020757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
    Reynolds LM; Infosino A; Brown R; Hsu J; Fisher DM
    Anesthesiology; 2000 Feb; 92(2):376-86. PubMed ID: 10691223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapacuronium: premarket drug evaluation can be very effective for the identification of drug risks.
    Lim R
    Anesth Analg; 2003 Feb; 96(2):631-2. PubMed ID: 12538231
    [No Abstract]   [Full Text] [Related]  

  • 29. The hemodynamic effects of rapacuronium in patients with coronary artery disease: succinylcholine and vecuronium compared.
    Delboy NJ; Tomichek RC; Shields JA
    Anesth Analg; 2002 May; 94(5):1100-6, table of contents. PubMed ID: 11973169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mivacurium--a new muscle relaxant compared with atracurium and vecuronium].
    Scholz J; von Knobelsdorff G; Peters K; Kycia B; Schulte am Esch J
    Anaesthesiol Reanim; 1997; 22(4):95-9. PubMed ID: 9376044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased mivacurium requirements and delayed neuromuscular recovery during sevoflurane anesthesia in children and adults.
    Bevan JC; Reimer EJ; Smith MF; Scheepers L deV ; Bridge HS; Martin GR; Bevan DR
    Anesth Analg; 1998 Oct; 87(4):772-8. PubMed ID: 9768768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapacuronium: why did it fail as a replacement for succinylcholine?
    White PF
    Br J Anaesth; 2002 Feb; 88(2):163-5. PubMed ID: 11878650
    [No Abstract]   [Full Text] [Related]  

  • 33. Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.
    Suzuki T; Lien CA; Belmont MR; Tjan J; Savarese JJ
    Can J Anaesth; 2003 Nov; 50(9):879-85. PubMed ID: 14617582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent.
    Larijani GE; Zafeiridis A; Goldberg ME
    Pharmacotherapy; 1999 Oct; 19(10):1118-22. PubMed ID: 10512060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of rapacuronium bromide.
    Wight WJ; Wright PM
    Clin Pharmacokinet; 2002; 41(13):1059-76. PubMed ID: 12403643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle.
    Jooste E; Zhang Y; Emala CW
    Anesthesiology; 2005 Jan; 102(1):117-24. PubMed ID: 15618795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter evaluation of the time-course of action of two doses of rapacuronium after early and late reversal with neostigmine.
    Larijani GE; Donati F; Bikhazi G; Bartkowski R; Kenaan CA; Plaud B; Goldberg ME
    Anesth Analg; 2001 Aug; 93(2):370-4 , 3rd contents page. PubMed ID: 11473863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapacuronium: clinical pharmacology.
    Mirakhur RK; McCourt KC
    Eur J Anaesthesiol Suppl; 2001; 23():77-82. PubMed ID: 11766252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mivacurium and bronchospasm.
    Bishop MJ
    Anesth Analg; 2004 Jan; 98(1):272. PubMed ID: 14693644
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of endogenous histamine in altered lung mechanics in rabbits.
    Habre W; Babik B; Chalier M; Peták F
    Anesthesiology; 2002 Feb; 96(2):409-15. PubMed ID: 11818775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.